Evidence map›Paper›PMID 35645216›Full record

ArticleInfectious disease reports2022

Implementing Early Phase Treatments for COVID-19 in Outpatient Settings: Challenges at a Tertiary Care Center in Italy and Future Outlooks.

Tommaso Manciulli, Filippo Lagi, Anna Barbiero, Marco Fognani, Nicoletta Di Lauria, Costanza Malcontenti, Costanza Fiorelli, Michele Spinicci, Vega Ceccherini, Paola D'Onofrio and 7 more

Abstract read
In one paragraph

Article in Infectious disease reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Tommaso ManciulliDepartment of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.ORCID 0000-0002-6846-8000
Filippo LagiDepartment of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.ORCID 0000-0003-0999-6070
Anna BarbieroDepartment of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.
Marco FognaniDepartment of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.
Nicoletta Di LauriaUnit of Infectious and Tropical Diseases, Careggi University Hospital, 50134 Florence, Italy.
Costanza MalcontentiUnit of Infectious and Tropical Diseases, Careggi University Hospital, 50134 Florence, Italy.
Costanza FiorelliUnit of Infectious and Tropical Diseases, Careggi University Hospital, 50134 Florence, Italy.
Michele SpinicciDepartment of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.ORCID 0000-0002-5377-7118
Vega CeccheriniHospital Management Unit, Careggi University Hospital, 50134 Florence, Italy.
Paola D'OnofrioHospital Management Unit, Careggi University Hospital, 50134 Florence, Italy.
Manuela AngileriHospital Pharmacy, Careggi University Hospital, 50134 Florence, Italy.
Francesca MalentacchiClinical Microbiology and Virology Unit, Careggi University Hospital, 50134 Florence, Italy.
Michele CecchiHospital Pharmacy, Careggi University Hospital, 50134 Florence, Italy.
Gian Maria RossoliniDepartment of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.
Matteo TomaiuoloHospital Management Unit, Careggi University Hospital, 50134 Florence, Italy.
Lorenzo ZammarchiDepartment of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.ORCID 0000-0003-0892-8404
Alessandro BartoloniDepartment of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.ORCID 0000-0001-9758-1523

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We present a brief commentary illustrating the current COVID-19 outpatient treatment options in Italy. We also report our experience setting up a service dedicated to these patients in the wake of the rise in COVID-19 cases observed in January 2022. We also gathered data on the daily costs faced by our outpatient service, based at a tertiary care center located in Florence, Italy. We present them with some considerations on future outlooks on the use of outpatient treatment in COVID-19.

Indexed as

molnupiravirmonoclonal antibodiesnirmatrelvir/ritonavirremdesivirSARS-CoV-2sotrovimab

Identifiers

PMID35645216
PMCPMC9149810

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.